119-s2336

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 2336 Introduced in Senate

    (IS) ]

<DOC>

119th CONGRESS
 1st Session
 S. 2336

 To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
 limited to naloxone.

_______________________________________________________________________

 IN THE SENATE OF THE UNITED STATES

 July 17, 2025

Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; 
 which was read twice and referred to the Committee on Health, 
 Education, Labor, and Pensions

_______________________________________________________________________

 A BILL

 To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
 limited to naloxone.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Halting the Epidemic of Addiction 
and Loss Act of 2025''.

SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT 
 PROGRAMS.

    (a) In General.--The Secretary of Health and Human Services shall 
ensure that, as appropriate, whenever the Department of Health and 
Human Services issues a regulation or guidance for any grant program 
addressing opioid misuse and use disorders, any reference to an opioid 
overdose reversal drug (such as a reference to naloxone) is inclusive 
of any opioid overdose reversal drug that has been approved under 

section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
for emergency treatment of a known or suspected opioid overdose.

    (b) Existing References.--

    (1) Update.--Not later than one year after the date of 
 enactment of this Act, the Secretary of Health and Human 
 Services shall update all references described in paragraph

    (2) to be inclusive of any opioid overdose reversal drug that has 
 been approved or otherwise authorized for use by the Food and 
 Drug Administration.

    (2) References.--A reference described in this paragraph is 
 any reference to an opioid overdose reversal drug (such as 
 naloxone) in any regulation or guidance of the Department of 
 Health and Human Services that--
        (A) was issued before the date of enactment of this 
 Act; and
        (B) is included in--
            (i) the grant program for State and Tribal 
 response to opioid use disorders under 

section 1003 of the 21st Century Cures Act (42 U.S.C. 
 290ee-3a) (commonly referred to as ``State 
 Opioid Response Grants'' and ``Tribal Opioid 
 Response Grants''); or
            (ii) the grant program for priority 
 substance use disorder prevention needs of 
 regional and national significance under 
 

section 516 of the Public Health Service Act 
 (42 U.S.C. 290bb-22).
 <all>